Podcast, Interview, Fireside Chat
When Two Giants Intersect: Healthcare Meets Fintech
- Healthcare entities are expected to evolve into fintech companies, treating financial technology as a third core pillar embedded within broader technology models.
- The price transparency law will trigger the publication of contracted rates by thousands of hospitals and hundreds of payers, with effects permeating the system over several years.
- Value-based payment models, such as Medicare Advantage, are predicted to align incentives differently but will remain in the early stages of industry adoption.
- The No Surprises Act is anticipated to limit liability for patients and providers regarding surprise out-of-network billing for specific services like anesthesiology.
- The Cures Act is expected to drive startup development of apps that consolidate medical records from multiple providers, displacing traditional fax or CD-ROM methods.
- The pandemic is projected to create urgency among historically slow-moving incumbents to adopt new technologies.
- Banking-as-a-service providers are expected to enable healthcare providers to embed lending, payments, and new card products at transactional points of intent.
- Providers will likely face working capital strain for up to 90 days or longer while awaiting insurance reimbursements.
- Juniper is forecast to receive payment between 3% and 5% for technology that programmatically improves health insurance claim submission efficiency.
- Juniper expects to extend credit to providers by leveraging statistical understanding of repayment probabilities and cash flow timing derived from processing 100% of provider revenue.
- Successful founders will require hybrid team DNA combining expertise in both healthcare and fintech to effectively navigate the intersection.
- Fintech entrepreneurs are expected to find success by applying vertical software playbooks and layering financial products into the healthcare sector.
- Insurtech and healthcare businesses face unique capital requirements necessitating investors knowledgeable about complex regulatory cash reserves and state-specific financial profiles.
- Employer-sponsored churn occurring over a few-year timeframe may create a mismatch for insurers investing in high upfront-cost, long-term ROI treatments like Ozempic or gene therapies.
- A consumer-centric underwriting solution is needed to distribute the financial burden of high-cost, one-time therapies across multiple carriers as individuals switch health plans.
- Traditional financial institutions are expected to accelerate the adoption of third-party technologies and cultivate authentic relationships with the startup ecosystem.
- Large financial and healthcare institutions continue to rely on human-driven workflows involving thousands of staff, reflecting operational states similar to or worse than the healthcare system.
- Major institutions are expected to recognize the necessity of engaging innovators to fundamentally transform businesses, reduce cost structures, and enhance consumer engagement.
- A specific convergence window is anticipated where innovator activities align with incumbent needs, creating a "superpower" dynamic for collaboration.
- Massive business opportunities are expected to emerge at the intersection of healthcare and fintech.